Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385958 | 0.92 | CYP1A2 (0.85) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL9638336 | 0.89 | CYP2C9 (0.87) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL21540376 | 0.86 | CYP1A2 (0.76) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL3363253 | 0.82 | KDM4E (0.82) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL10616433 | 0.78 | ALDH1A1 (0.68) | CYP1A2ALDH1A1HPGDCYP2C9KDM4E | |
| SCHEMBL14426507 | 0.78 | ALDH1A1 (0.62) | CYP1A2ALDH1A1HPGDCYP2C9KDM4E | |
| SCHEMBL503767 | 0.78 | SRD5A2 (1.00) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL29460235 | 0.78 | SRD5A2 (1.00) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL31156436 | 0.77 | KDM4E (0.74) | CYP1A2ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL25970319 | 0.77 | KDM4E (0.74) | CYP1A2ALDH1A1HPGDCYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-11-05 | — | — | US | disclosed |
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-11-05 | — | — | US | disclosed |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-24 | — | — | US | disclosed |
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-03 | — | — | US | disclosed |
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-03 | — | — | US | disclosed |
| EP-2816034-B1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INST BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK (PL) | 2018-12-12 | — | — | EP | disclosed |
| EP-2826771-B1 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INST BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK (PL) | 2018-12-12 | — | — | EP | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-01-07 | — | — | US | disclosed |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-01-07 | — | — | US | disclosed |
| EP-2616444-B1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INST BIOCHEMII I BIOFIZYKI PAN (PL) | 2015-08-26 | — | — | EP | disclosed |
| EP-2826771-A2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2816035-A2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) | 2014-12-24 | — | — | EP | disclosed |
| EP-2816034-A2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) | 2014-12-24 | — | — | EP | disclosed |
| EP-2816034-A2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) | 2014-12-24 | — | — | EP | disclosed |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2013-11-14 | — | — | US | disclosed |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2013-11-14 | — | — | US | disclosed |
| WO-2012036573-A2 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TMEM120A | CYP1A2 4162/4885ALDH1A1 3701/4885HPGD 4175/4885 |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | CYP1A2 3709/4885ALDH1A1 3883/4885HPGD 4082/4885 |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TCOF1, ABCC2 | CYP1A2 3328/4885ALDH1A1 4338/4885HPGD 3990/4885 |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TCOF1 | CYP1A2 3709/4885ALDH1A1 3883/4885HPGD 4082/4885 |
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | CYP1A2 3709/4885ALDH1A1 3883/4885HPGD 4082/4885 |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TMEM120A | CYP1A2 4162/4885ALDH1A1 3701/4885HPGD 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.